Is Antazoline + Naphazoline registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 2 valid registrations of Antazoline + Naphazoline, including APIHIST EYE\NOSE DROP (5,0.25 mg,mg, Eye/nose drops, SAR 1.70); OCURED (5,0.25 mg,mg, Eye drops, SAR 8.10).

Is Antazoline + Naphazoline approved by the US FDA?

Drugs@FDA lists 1 application product line for Antazoline + Naphazoline, including VASOCON-A (Discontinued).

Active substances

Antazoline + Naphazoline

SFDA 4
US FDA 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
APIHIST EYE\NOSE DROP	5,0.25 mg,mg	Eye/nose drops · Ophthalmic use	1 Dropper Container	SAR 1.70	Generic · Prescription	Amman Pharmaceutical Industries (API)	Valid
OCURED	5,0.25 mg,mg	Eye drops · Ophthalmic use	1 Dropper Container	SAR 8.10	Generic · Prescription	RIYADH PHARMA	Valid
NAZOLIN NASAL DROPS	0.5, 0.025 mg/ml	Suspension · Nasal use	1 Dropper Container	SAR 1.90	Generic · OTC	DAR ALDAWA	Withdrawn by MAH · Not Marketed
NOSCAM	0.5, 0.025 %	Nasal drops · Topical	1 Dropper Container	SAR 5.85	Generic · OTC	RIYADH PHARMA	Withdrawn by MAH · Not Marketed

Indications — CHI Daman Drug Formulary

ALLERGIC CONJUCTIVITIS (AC); ALLERGIC RHINITIS; VIRAL CONJUNCTIVITS, HERPESVIRAL KERATITIS, HERPESVIRAL CONJUNCTIVITIS, VARICELLA KERATITIS, ZOSTER CONJUNCTIVITIS, ZOSTER KERATITIS, MEASLES KERATITIS AND KERATOCONJUNCTIVITIS, VIRAL CONJUNCTIVITIS, KERATITIS

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
VASOCON-A	0.5%;0.05%	solution/drops · ophthalmic	NOVARTIS	Discontinued	30 Apr 1990

Components

Naphazoline

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.